《大行報告》匯豐研究升美高梅中國(02282.HK)目標價至15元 今年開局良好
匯豐研究發表報告指出,美高梅中國(02282.HK)去年第四季季績再次超預期,期內物業EBITDA為2.79億美元,相當於2019年水平的140%,按季增長16%,並較該行預期的2.54億美元為高。公司上季包括大規模再投資在內的營運開支增長與淨收入增長一致,捍衛公司毛利。
該行認為,美高梅中國今年首季開局良好,市佔率呈現強勁趨勢,1月份市場份額高達20%。該行將公司今明兩年的EBITDA預測上調1%至2%,以反映前景改善及嚴格的成本控制影響。對其目標價由14.5元上調至15元,維持「買入」評級,認為公司估值不高。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.